Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631631 · ClinicalTrials.gov registry record
Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
A clinical trial, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- 205
- Enrollment target
NCT00631631: Completed study, sponsored by Millennium Pharmaceuticals.
NCT00631631 is a clinical trial that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 205 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00631631 has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- 205 participants
- Enrollment target
Study Summary
The purpose of this study was to collect information regarding the safety and tolerability of mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; L-MTP-PE).
Interventions
- DRUG Mifamurtide (L-MTP-PE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-10 |
What the finished NCT00631631 record still lists
NCT00631631 is an observational study that tracks outcomes without assigning an intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Mifamurtide (L-MTP-PE) is the first listed.
NCT00631631 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00631631 about?
NCT00631631 is a clinical study titled "Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma". The purpose of this study was to collect information regarding the safety and tolerability of mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; L-MTP-PE).
What is the current status of trial NCT00631631?
This trial is currently completed. The enrollment target is 205 participants. The study started on 2008-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00631631?
The interventions under investigation include: Mifamurtide (L-MTP-PE) (DRUG).
Who is sponsoring clinical trial NCT00631631?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia